• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Itvisma

Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients

By Soujanya Ravi on April 24, 2026   Pharma & Biotech  

Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients

Novartis Pharma AG’s Itvisma gains CHMP support in SMA. Find out how gene therapy could reshape treatment for older patients in Europe.

Recent Posts

  • Phillips Medisize targets formulation-device risk as inhaled therapies grow more complex
  • Could TRexBio’s Treg bet crack the next big frontier in atopic dermatitis?
  • Fujifilm’s ELUXEO 8000 and EG-840TP pairing raises the bar in interventional endoscopy
  • Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy
  • Can PharmaJet’s needle-free Tropis system help Nigeria close its polio gap?
  • Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
  • Why Encompass Health is betting on a fast-growing Texas suburb before rivals crowd in
  • What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts
  • Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown
  • Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering
  • Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
  • Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes